Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5287 Target Snapshot

Hepatic sodium/bile acid cotransporter · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
227Compounds
74Assays
12Approved Drugs
228.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Hepatic sodium/bile acid cotransporter shows approved-linked disease relevance led by hepatitis D virus infection. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q14973. Start with hepatitis D virus infection, then reuse UniProt Q14973 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with hepatitis D virus infection, then reuse UniProt Q14973 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
hepatitis D virus infection

Hepatic sodium/bile acid cotransporter shows approved-linked disease relevance led by hepatitis D virus infection. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with hepatitis D virus infection because it currently carries approved-linked support. Linked drugs include BULEVIRTIDE ACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Hepatic sodium/bile acid cotransporter as ChEMBL target CHEMBL5287, mapped to UniProt Q14973. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Hepatic sodium/bile acid cotransporter
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5287
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q14973
Hepatic sodium/bile acid cotransporter
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Hepatic sodium/bile acid cotransporter is the right protein anchor across sources, using UniProt Q14973 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why hepatitis D virus infection is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameHepatic sodium/bile acid cotransporter
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ14973
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelHepatic sodium/bile acid cotransporter
UniProt AccessionQ14973
Component TypeProtein
Sequence Length349 aa

Hepatic sodium/bile acid cotransporter

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Hepatic sodium/bile acid cotransporter, mapped to UniProt Q14973. Sequence length is 349 aa.

Mapped IDQ14973
Review nameHepatic sodium/bile acid cotransporter
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Hepatic sodium/bile acid cotransporter shows approved-linked disease relevance led by hepatitis D virus infection. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
hepatitis D virus infection
1 linked drug · 1 direct · 1 efficacy
Linked drugBULEVIRTIDE ACETATE
Approved-linked Approved
Hepatitis Delta Virus
1 linked drug · 1 direct · 1 efficacy
Linked drugBULEVIRTIDE ACETATE
Approved-linked Approved
viral disease
1 linked drug · 1 direct · 1 efficacy
Linked drugBULEVIRTIDE
Late clinical Phase III
chronic hepatitis
1 linked drug · 1 direct · 1 efficacy
Linked drugBULEVIRTIDE
Late clinical Phase III
chronic hepatitis C virus infection
1 linked drug · 1 direct · 1 efficacy
Linked drugBULEVIRTIDE
Clinical signal Phase II
hepatitis D virus infection
3 linked drugs · 3 direct · 3 efficacy
Linked drugBULEVIRTIDE
Linked drugHEPALATIDE
Linked drugMYRCLUDEX B
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with hepatitis D virus infection because it currently carries approved-linked support. Linked drugs include BULEVIRTIDE ACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasehepatitis D virus infection
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

12
Approved
3
Phase III
1
Phase II
Assay Mix

Activity Type Distribution

IC5081.0
KI8.0
EC50138.0
KD1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4875567 9.52 IC50 0.3 Preclinical
CHEMBL6000938 8.74 EC50 1.8 Preclinical
CHEMBL5995946 8.72 EC50 1.9 Preclinical
CHEMBL5931719 8.68 EC50 2.1 Preclinical
CHEMBL6057770 8.68 EC50 2.1 Preclinical
CHEMBL5946125 8.54 EC50 2.9 Preclinical
CHEMBL5795613 8.51 EC50 3.1 Preclinical
CHEMBL5741380 8.49 EC50 3.2 Preclinical
CHEMBL5814839 8.49 EC50 3.2 Preclinical
CHEMBL5768748 8.43 EC50 3.7 Preclinical
Distribution

pChEMBL Value Distribution

24
5.0
3
5.5
4
6.0
33
6.5
45
7.0
50
7.5
23
8.0
6
8.5
0
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

CYCLOSPORINE
CHEMBL160
Approved 1983
Properties Compare Identifier
Assay Landscape

Assay Landscape

75
Total Assays
190
Tested Compounds
2
Assay Types
Binding — 50 assays, 190 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 41 46 6.0
single protein format 8 9 4.9
assay format 1 135 7.5
Functional — 25 assays, 8 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 25 8 5.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine